Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
BörsenkürzelAKYA
Name des UnternehmensAkoya Biosciences Inc
IPO-datumApr 16, 2021
CEOMr. Brian Mckelligon
Anzahl der mitarbeiter205
WertpapierartOrdinary Share
GeschäftsjahresendeApr 16
Addresse100 Campus Drive
StadtMARLBOROUGH
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl01762
Telefon18558968401
Websitehttps://www.akoyabio.com/
BörsenkürzelAKYA
IPO-datumApr 16, 2021
CEOMr. Brian Mckelligon
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten